TP53 and acute myeloid leukemia: We further identify inhibition of the mevalonate pathway as a potential therapeutic vulnerability of TP53-mutant AML cells, and stimulation of the Wnt pathway as a promising avenue to enhance the efficacy of CAR T-cell therapy.